Gyre Therapeutics (GYRE) Non-Current Deferred Tax Liability (2023 - 2025)
Gyre Therapeutics (GYRE) posted quarterly Non-Current Deferred Tax Liability of $9.6 million for Q4 2025, up 15.66% year-over-year from $8.3 million in Q4 2024, and up 15.66% quarter-over-quarter from $8.3 million in Q4 2024.
Gyre Therapeutics (GYRE) Non-Current Deferred Tax Liability (2023 - 2025) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Non-Current Deferred Tax Liability for 3 consecutive years, with $9.6 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Non-Current Deferred Tax Liability rose 15.66% year-over-year to $9.6 million; the TTM figure through Dec 2025 stood at $9.6 million (up 15.66% YoY), while the FY2025 annual figure was $9.6 million, up 15.66% from the prior year.
- Non-Current Deferred Tax Liability climbed to $9.6 million in Q4 2025 per GYRE's latest filing, from $8.3 million in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $9.6 million in Q4 2025 and bottomed at $2.5 million in Q4 2023.
- Historically, Non-Current Deferred Tax Liability has averaged $6.8 million across 3 years, with a median of $8.3 million in 2024.
- Annual changes were most pronounced in 2024 — Non-Current Deferred Tax Liability surged 232.0% — and 2025, when it climbed 15.66%.
- Gyre Therapeutics' Non-Current Deferred Tax Liability stood at $2.5 million in 2023, then soared by 232.0% to $8.3 million in 2024, then rose by 15.66% to $9.6 million in 2025.
- Business Quant data shows GYRE's Non-Current Deferred Tax Liability at $9.6 million in Q4 2025, $8.3 million in Q4 2024, and $2.5 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 9.60 Mn |
| Dec 31, 2025 | 9.60 Mn |
| Dec 31, 2024 | 8.30 Mn |
| Dec 31, 2024 | 8.30 Mn |
| Dec 31, 2023 | 2.50 Mn |
| Dec 31, 2023 | 2.50 Mn |